Compounds > 1-(2-chloroimidazo(1,2-a)pyridin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)urea
Page last updated: 2024-12-07
1-(2-chloroimidazo(1,2-a)pyridin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)urea
Description
The compound 1-(2-chloroimidazo(1,2-a)pyridin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)urea is a **synthetic organic molecule**, specifically a **urea derivative**. It's not a naturally occurring compound but was likely designed and synthesized in a laboratory.
**Without further context**, it's impossible to definitively state its exact importance for research. However, based on its structure, here are some potential reasons why it might be significant:
* **Pharmacological Activity:**
* **Urea Derivatives:** Ureas are known to exhibit various pharmacological activities, including anti-inflammatory, analgesic, and anti-cancer properties.
* **Heterocyclic Rings:** The imidazopyridine and pyrimidine rings are common structural motifs in pharmaceuticals, often associated with interactions with biological targets like enzymes or receptors.
* **Sulfonyl Group:** The sulfonyl group can influence a molecule's solubility and interactions with biomolecules.
* **Substituents:** The chloro and methoxy groups can affect the compound's overall properties, including its activity and selectivity.
* **Lead Compound for Drug Development:** This compound might be a lead compound for developing new drugs targeting specific disease pathways.
* **Chemical Probe:** It could be a chemical probe to investigate the function of specific biological targets or pathways.
* **Building Block for Synthesis:** It could be an important building block for synthesizing other more complex organic molecules.
**To determine its exact significance for research, you'd need more information:**
* **What research area is it being studied in?** (e.g., cancer, inflammation, infectious diseases)
* **What are its biological activities?** (e.g., binding affinity, enzyme inhibition)
* **What are the specific research goals?** (e.g., drug discovery, target validation)
By understanding the context, you can better understand the importance of this specific compound in scientific research.
1-(2-chloroimidazo(1,2-a)pyridin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)urea: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 92433 |
| CHEBI ID | 81751 |
| SCHEMBL ID | 55236 |
| MeSH ID | M0396326 |
Synonyms (32)
| Synonym |
|---|
| 122548-33-8 |
| imazosulfuron [iso] |
| 1-(2-chloroimidazo(1,2-a)pyridin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)urea |
| imidazo(1,2-a)pyridine-3-sulfonamide, 2-chloro-n-(((4,6-dimethoxy- 2-pyrimidinyl)amino)carbonyl)- |
| th 913 |
| imazosulfuron |
| nagrvuxekkznht-uhfffaoysa- |
| 1-(2-chloroimidazo[3,2-a]pyridin-3-yl)sulfonyl-3-(4,6-dimethoxypyrimidin-2-yl)ur |
| inchi=1/c14h13cln6o5s/c1-25-9-7-10(26-2)18-13(17-9)19-14(22)20-27(23,24)12-11(15)16-8-5-3-4-6-21(8)12/h3-7h,1-2h3,(h2,17,18,19,20,22) |
| 1-(2-chloroimidazo[1,2-a]pyridin-3-yl)sulfonyl-3-(4,6-dimethoxypyrimidin-2-yl)urea |
| C18443 |
| unii-27luj2bjdg |
| hsdb 8448 |
| 27luj2bjdg , |
| 1-(2-chloroimidazo[1,2-a]pyridin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)urea |
| AKOS015903895 |
| SCHEMBL55236 |
| brazzos |
| 2-chloro-n-(((4,6-dimethoxy-2-pyrimidinyl)amino)carbonyl)imidazo(1,2-a)pyridine-3-sulfonamide |
| takeoff |
| th-913 |
| imazosulfuron [mi] |
| CHEBI:81751 |
| DTXSID2057946 |
| NAGRVUXEKKZNHT-UHFFFAOYSA-N |
| n-(2-chloroimidazo[1,2-a]pyridine-3-ylsulfonyl)-n'-(4,6-dimethoxy-2-pyrimidinyl)urea |
| J-004822 |
| imazosulfuron, pestanal(r), analytical standard |
| 2-chloro-n-(4,6-dimethoxypyrimidin-2-ylcarbamoyl)imidazo[1,2-a]pyridine-3-sulfonamide |
| Q22808274 |
| imidazo[1,2-a]pyridine-3-sulfonamide, 2-chloro-n-[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]- |
| [1,2-a]pyridine-3-sulfonamide, 2-chloro-n-[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]- |
Research Excerpts
Dosage Studied
Drug Classes (1)
| Class | Description |
|---|
| imidazopyridine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.76 (24.57) | | Research Supply Index | 2.56 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (8.33%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |